OranssiBio is dedicated to partnering with our customers to bring innovative therapies to patients worldwide. With our advanced state-of-the-art facilities and cutting-edge technology platforms, we are able to provide comprehensive support from early-stage development, clinical supply, all the way to commercial manufacturing, ensuring the highest quality standards and regulatory compliance throughout the process.

Platform AAV LV Exosome Cell Plasmid DNA
Cell Line Development ✓ ✓ ✓ ✓ N/A
Process Development ✓ ✓ ✓ ✓ ✓
Analytical Method Qualification / Validation ✓ ✓ ✓ ✓ ✓
Clinical Batch Manufacturing ✓ ✓ ✓ ✓ ✓
Analytics for Clinical Batch Release and Stability Study ✓ ✓ ✓ ✓ ✓

Below is a list of the products we provided. These products are made using serum free suspension production systems. We are happy to customize your order if a different volume, titer, purity or a different production system is needed.

Item Catalog # Product Name Titer Size Price (USD) Standard Timeline To Order
LV 200101 LV-VSVG-GFP > 107 TU/ml >30μl 100-400 2-3 weeks
LV 200102 LV-BaEV-GFP > 107 TU/ml >30μl 100-400 2-3 weeks
Exsome 300001 Ex-HEK293 > 109 particles/ml >30μl 100-400 2-3 weeks
Exsome 300010 Ex-IPSC (neonatal foreskin cells) > 109 particles/ml >30μl 100-400 2-3 weeks
AAV 100001 AAV1-Empty Capsids > 1013 VP/ml >30μl 100-400 2-3 weeks
AAV 100002 AAV2-Empty Capsids > 1012 VP/ml >30μl 100-400 2-3 weeks
AAV 100005 AAV5-Empty Capsids > 1013 VP/ml >30μl 100-400 2-3 weeks
AAV 100006 AAV6-Empty Capsids > 1013 VP/ml >30μl 100-400 2-3 weeks
AAV 100008 AAV8-Empty Capsids > 1013 VP/ml >30μl 100-400 2-3 weeks
AAV 100009 AAV9-Empty Capsids > 1013 VP/ml >30μl 100-400 2-3 weeks
AAV 100101 AAV1-GFP > 1013 VG/ml >30μl 100-400 2-3 weeks
AAV 100102 AAV2-GFP > 1012 VG/ml >30μl 100-400 2-3 weeks
AAV 100105 AAV5-GFP > 1013 VG/ml >30μl 100-400 2-3 weeks
AAV 100106 AAV6- GFP > 1013 VG/ml >30μl 100-400 2-3 weeks
AAV 100108 AAV8- GFP > 1013 VG/ml >30μl 100-400 2-3 weeks
AAV 100109 AAV9-GFP > 1013 VG/ml >30μl 100-400 2-3 weeks